Aging is a complex process that results from a combination of environmental, genetic, and epigenetic factors. A chronic, low-grade, systemic inflammation (inflammaging) is a pervasive feature of aging, and can trigger a variety of common diseases that appear as we get older, including, arthritis, cancer, heart disease, type 2 diabetes, and Alzheimer’s disease.
Pan-Biome is a preclinical biopharmaceutical company focused on age-related diseases and increasing human healthspan. Pan-Biome’s lead compound activates anti-inflammatory cytokine IL-10 and inhibits the major pro-inflammatory cytokines TNF-a, IL-1b, and IL-6. These cytokines contribute significantly to inflammaging in healthy elderly individuals while also playing a major role in age-related diseases. Pan-Biome’s compound also activates AMPK and Nrf2, master regulators of the aging process.
Who We’re Working With
Contact
Investor Inquiries:
Gordon Eberwein
geberwein@derm-biome.com
https://derm-biomepharmaceuticals.com/
https://pan-biomepharmaceuticals.com/